Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HWASEUNG Industries Co.,Ltd. (006060.KS)
Busan, KR
Hwaseung Industries Co.,Ltd., a South Korean enterprise established in 1969, maintains its headquarters in Busan. The company operates globally, with core activities centered on the manufacturing of footwear and a diverse range of precision chemical products. Its chemical portfolio encompasses films such as BOPP, PET, and specialized air quality films, as well as various sheets and plates. It also specializes in synthetic resins and numerous adhesives, including formulations for shoes, industrial applications, automotive coatings, and polyurethane. Beyond manufacturing, Hwaseung Industries is also involved in the commerce of apparel, bedding, and other related goods.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.46% | -7.73% | -5.66% | -7.86% | -17.69% | -12.33% | -30.97% | -14.34% | -61.40% | -56.64% | +741.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-4.6% Q1'26: -15.9% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-50.0% Q1'26: -59.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+6.5% ★ Q1'26: -8.2% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+4.1% Q1'26: +2.1% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+3.9% Q1'26: +1.7% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+11.7% Q1'26: -2.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×4.80× Q1'26: 7.18× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
1.01T
est: 1.01T (0.0%)
|
1.15T
est: 1.31T (-12.4%)
|
1.11T
est: 1.14T (-2.3%)
|
1.43T
est: 1.38T (+3.3%)
|
1.30T
est: 1.40T (-7.4%)
|
1.37T
est: 1.66T (-17.9%)
|
1.91T
est: 1.89T (+1.1%)
|
| EBITDA |
104.33B
est: 87.80B (+18.8%)
|
118.79B
est: 114.13B (+4.1%)
|
100.08B
est: 98.81B (+1.3%)
|
175.45B
est: 119.88B (+46.4%)
|
143.80B
est: 121.75B (+18.1%)
|
98.74B
est: 144.34B (-31.6%)
|
133.85B
est: 164.32B (-18.5%)
|
| EBIT |
77.42B
est: 37.74B (+105.1%)
|
83.51B
est: 49.06B (+70.2%)
|
51.77B
est: 42.48B (+21.9%)
|
120.55B
est: 51.53B (+133.9%)
|
78.87B
est: 52.34B (+50.7%)
|
27.65B
est: 62.04B (-55.4%)
|
48.68B
est: 70.64B (-31.1%)
|
| Net Income |
44.48B
est: 40.17B (+10.7%)
|
36.46B
est: 52.20B (-30.2%)
|
20.31B
est: 13.03B (+55.9%)
|
80.88B
est: 52.23B (+54.9%)
|
49.92B
est: 38.58B (+29.4%)
|
-4.20B
est: 51.46B (-108.2%)
|
84.44M
est: 67.61B (-99.9%)
|
| SGA |
25.72B
est: 38.68B (-33.5%)
|
31.27B
est: 50.29B (-37.8%)
|
33.91B
est: 43.54B (-22.1%)
|
45.91B
est: 52.82B (-13.1%)
|
40.96B
est: 53.65B (-23.6%)
|
51.01B
est: 63.60B (-19.8%)
|
73.51B
est: 72.40B (+1.5%)
|
| EPS |
809.00
est: 811.00 (-0.2%)
|
663.00
est: 1,054.00 (-37.1%)
|
370.00
est: 263.00 (+40.7%)
|
1,498.77
est: 1,054.50 (+42.1%)
|
932.78
est: 779.00 (+19.7%)
|
-79.49
est: 1,039.00 (-107.7%)
|
1.65
est: 1,365.00 (-99.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.00% | 36.0K | 0.15% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 75.9K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 49.7K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 37.2K | 0.28% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 333.25 | 0.56% |
| 6 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 17.8K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bong-Ho Lee | Senior MD & Director | — | male |
| Chan-Ho Lee | MD & Director | — | male |
| Seok-Ho Hyun | Chief Executive Officer & Vice-Chairperson | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 006060.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
